Reduced folate carrier gene is a risk factor for neural tube defects in a Chinese population

Lijun Pei1, Huiping Zhu, Aiguo Ren

  • 1Institute of Reproductive and Child Health, Peking University Health Science Center, No. 38 Xueyuan Road, Haidian District, Beijing 100083, China. Peilj@healthychildren.org.cn

Insights

A specific gene variant (RFC1 GG genotype) increases the risk of neural tube defects (NTDs). This risk is significantly higher when mothers do not supplement with folic acid during pregnancy.

Area of Science:

  • Genetics
  • Maternal Health
  • Developmental Biology

Background:

  • Folic acid supplementation significantly reduces neural tube defects (NTDs).
  • The precise mechanism of folic acid's protective effect is unknown.
  • Folate transporter genes, like RFC1, are potential NTD risk factors.

Purpose of the Study:

  • Investigate the association between RFC1 polymorphism (A80G) and NTD risk.
  • Examine gene-environment interactions between infant RFC1 genotype and maternal folic acid use.

Main Methods:

  • Population-based case-control study.
  • Included 104 nuclear families with NTDs and 100 control families.
  • Analyzed RFC1 A80G polymorphism in offspring and maternal folic acid intake.

Main Results:

  • Infants with RFC1 GG genotype had a 2.56-fold increased NTD risk compared to AA genotype.
  • Mothers not using folic acid had higher NTD risk for GG genotype offspring (OR 3.30).
  • Combined GG genotype and no folic acid use elevated NTD risk significantly (OR 8.80) compared to supplemented mothers.

Conclusions:

  • The RFC1 G allele is a significant genetic factor in folate transport.
  • This RFC1 polymorphism may be a risk factor for NTDs in the Chinese population.
  • Maternal folic acid supplementation mitigates the risk associated with the RFC1 GG genotype.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the anterior...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...